INB03

Patients with advance solid tumors (advanced cancer with metastasis) who have elevated number of MDSC in their blood will be eligible.  The clinical trial is designed as a standard open label dose-escalation trial using biomarkers for patients selection.

Patients with advanced melanoma who have been treated with CPI in the past but were found to be resistant to CPI or have developed refractory disease (progression on CPI) who have increased MDSC in their blood will be eligible.  The clinical trial will be a Phase II, open label dose escalation trial with two arms, resistant disease and refractory disease.  Patients will be treated with INB03 in combination with CPI.

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST